First Tracks Biotherapeutics Launches with $180 Million Cash on Nasdaq
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Source: Newsfilter
- Company Launch and Funding: First Tracks Biotherapeutics officially launches today with $180 million in cash, ensuring a two-year operational runway aimed at advancing antibody therapeutics for autoimmune and inflammatory diseases.
- Product Pipeline Overview: The company will initially focus on three development-stage assets, including the CD122 antagonist ANB033 for celiac disease and eosinophilic esophagitis, which is currently in a Phase 1b trial, indicating strong market potential.
- Shareholder Distribution Details: The spin-off was completed by distributing one share of First Tracks Bio common stock for each share of AnaptysBio held as of April 6, 2026, enhancing shareholder investment value.
- Market Outlook: CEO Daniel Faga emphasized the commitment to developing antibody therapies for autoimmune diseases, which are expected to deliver significant therapeutic benefits to patients and drive long-term value creation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRAX
Wall Street analysts forecast TRAX stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 18.170
Low
Averages
High
Current: 18.170
Low
Averages
High
About TRAX
First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The Company's clinical-stage pipeline includes Rosnilimab, a selective pathogenic T cell depleter, for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator. Rosnilimab is an IgG1 antibody that directly targets pathogenic T cells, such as activated Tph/Tfh and T effector cells, in the periphery or inflamed tissue. Rosnilimab is designed to selectively deplete pathogenic T cells while sparing non-pathogenic T cells, including naive T cells, to preserve overall immune function and restore immune homeostasis. Its molecules have applicability across a range of autoimmune and inflammatory diseases, including gastroenterology, rheumatology and other areas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Ratings Overview
- BofA Upgrades Brown-Forman: Bank of America upgraded Brown-Forman from underperform to neutral, citing better-than-expected Q4/FY26 results and consistent sales delivery, indicating a more constructive outlook that could enhance market performance.
- Goldman Sachs Upgrades W.R. Berkley: Goldman Sachs upgraded W.R. Berkley from neutral to buy, believing that sustainable underwriting activity will yield long-term benefits for investors, reflecting stability and growth potential in the insurance sector.
- Morgan Stanley Initiates Cerebras: Morgan Stanley initiated coverage on Cerebras with an overweight rating, highlighting unique demand for low-latency inference solutions that is driving growth, with projected revenues of $6 billion by 2028 indicating a strong market outlook.
- UBS Upgrades Cummins: UBS upgraded Cummins from neutral to buy and raised the price target to $850, anticipating double-digit growth in its power division and the rollout of new engines to drive earnings growth over the next two years.
See More
Veru Shares Surge 88% on Novo Nordisk Collaboration
- Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
- Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
- Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
- Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
See More
Turn Therapeutics Stock Rises 20% on Positive Trial Results
- Clinical Trial Results: Turn Therapeutics Inc. (TTRX) reported that 92.6% of subjects in its phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis achieved a 50% reduction in eczema severity within four weeks, leading to a stock price increase of over 20%, indicating strong market potential for the drug.
- Optimization Strategy Implementation: The company is refining its trial strategy based on interim analysis results by adjusting enrollment criteria to balance baseline disease severity and body surface area, which is expected to enhance the likelihood of success in subsequent phases and boost investor confidence.
- New Product Development: Conexeu Sciences Inc. (CNXU) saw its stock rise over 18% following its Nasdaq listing, as it launched the B.R.E.A.S.T. bioprinting project, marking a strategic entry into multi-billion-dollar markets, with plans to submit a 510(k) application in early 2027, advancing the product towards clinical trials.
- Strategic Transformation: LIXTE Biotechnology Holdings Inc. (LIXT) announced a shift towards an AI energy infrastructure equipment and services platform, resulting in a stock price increase of over 15%, which not only addresses the rapidly growing power demands in North America but also seeks a strategic partner for its clinical-stage pharmaceutical operations, showcasing a diversified future direction for the company.
See More
First Tracks Biotherapeutics Reports Q1 Losses and Cash Reserves
- Net Loss Overview: First Tracks Biotherapeutics reported a net loss of $50.5 million for the three months ended March 31, 2026, compared to a loss of $47.2 million in the same period of 2025, indicating ongoing financial pressure that may affect investor confidence.
- R&D Expense Trends: Research and development expenses decreased to $34.0 million in Q1 2026 from $41.5 million in Q1 2025, primarily due to reduced development costs for rosnilimab and ANB032, offset by increased costs related to phase 1 trials for ANB033, reflecting a strategic shift in R&D focus.
- Administrative Cost Increase: General and administrative expenses rose to $18.9 million in Q1 2026 from $9.8 million in Q1 2025, largely due to legal costs associated with the company's separation and allocations for non-cash stock compensation, which may impact operational efficiency.
- Cash Reserves Status: Upon launch on April 20, 2026, First Tracks had $180 million in cash and cash equivalents, which, while substantial, may not sustain long-term testing needs if R&D progress does not accelerate, potentially affecting future market competitiveness.
See More
AnaptysBio Completes Spin-Off, Focuses on Royalty Management
- Spin-Off Completion: AnaptysBio has successfully completed its spin-off of First Tracks Biotherapeutics, distributing one share of First Tracks stock for each share of Anaptys held, marking a strategic shift aimed at enhancing shareholder value.
- Virtual Business Model: The new structure operates under a virtual business model with minimal operating expenses and limited full-time employees, projecting an EBIT margin exceeding 95%, which will enhance efficiency in managing royalties and improve profitability.
- Focus on Royalty Management: AnaptysBio will concentrate on managing financial collaborations with GSK and Vanda, particularly for Jemperli and imsidolimab, with the goal of protecting and enhancing the value of these assets to boost shareholder returns.
- Future Outlook: The company will continue trading on Nasdaq under the ticker ANAB, while First Tracks stock will also commence trading, indicating ongoing activity in the capital markets and suggesting future growth potential.
See More
First Tracks Biotherapeutics Launches with $180 Million Cash on Nasdaq
- Company Launch and Funding: First Tracks Biotherapeutics officially launches today with $180 million in cash, ensuring a two-year operational runway aimed at advancing antibody therapeutics for autoimmune and inflammatory diseases.
- Product Pipeline Overview: The company will initially focus on three development-stage assets, including the CD122 antagonist ANB033 for celiac disease and eosinophilic esophagitis, which is currently in a Phase 1b trial, indicating strong market potential.
- Shareholder Distribution Details: The spin-off was completed by distributing one share of First Tracks Bio common stock for each share of AnaptysBio held as of April 6, 2026, enhancing shareholder investment value.
- Market Outlook: CEO Daniel Faga emphasized the commitment to developing antibody therapies for autoimmune diseases, which are expected to deliver significant therapeutic benefits to patients and drive long-term value creation.
See More
Latest Wall Street Ratings Overview
- BofA Upgrades Brown-Forman: Bank of America upgraded Brown-Forman from underperform to neutral, citing better-than-expected Q4/FY26 results and consistent sales delivery, indicating a more constructive outlook that could enhance market performance.
- Goldman Sachs Upgrades W.R. Berkley: Goldman Sachs upgraded W.R. Berkley from neutral to buy, believing that sustainable underwriting activity will yield long-term benefits for investors, reflecting stability and growth potential in the insurance sector.
- Morgan Stanley Initiates Cerebras: Morgan Stanley initiated coverage on Cerebras with an overweight rating, highlighting unique demand for low-latency inference solutions that is driving growth, with projected revenues of $6 billion by 2028 indicating a strong market outlook.
- UBS Upgrades Cummins: UBS upgraded Cummins from neutral to buy and raised the price target to $850, anticipating double-digit growth in its power division and the rollout of new engines to drive earnings growth over the next two years.
See More
Veru Shares Surge 88% on Novo Nordisk Collaboration
- Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
- Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
- Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
- Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
See More
Turn Therapeutics Stock Rises 20% on Positive Trial Results
- Clinical Trial Results: Turn Therapeutics Inc. (TTRX) reported that 92.6% of subjects in its phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis achieved a 50% reduction in eczema severity within four weeks, leading to a stock price increase of over 20%, indicating strong market potential for the drug.
- Optimization Strategy Implementation: The company is refining its trial strategy based on interim analysis results by adjusting enrollment criteria to balance baseline disease severity and body surface area, which is expected to enhance the likelihood of success in subsequent phases and boost investor confidence.
- New Product Development: Conexeu Sciences Inc. (CNXU) saw its stock rise over 18% following its Nasdaq listing, as it launched the B.R.E.A.S.T. bioprinting project, marking a strategic entry into multi-billion-dollar markets, with plans to submit a 510(k) application in early 2027, advancing the product towards clinical trials.
- Strategic Transformation: LIXTE Biotechnology Holdings Inc. (LIXT) announced a shift towards an AI energy infrastructure equipment and services platform, resulting in a stock price increase of over 15%, which not only addresses the rapidly growing power demands in North America but also seeks a strategic partner for its clinical-stage pharmaceutical operations, showcasing a diversified future direction for the company.
See More
First Tracks Biotherapeutics Reports Q1 Losses and Cash Reserves
- Net Loss Overview: First Tracks Biotherapeutics reported a net loss of $50.5 million for the three months ended March 31, 2026, compared to a loss of $47.2 million in the same period of 2025, indicating ongoing financial pressure that may affect investor confidence.
- R&D Expense Trends: Research and development expenses decreased to $34.0 million in Q1 2026 from $41.5 million in Q1 2025, primarily due to reduced development costs for rosnilimab and ANB032, offset by increased costs related to phase 1 trials for ANB033, reflecting a strategic shift in R&D focus.
- Administrative Cost Increase: General and administrative expenses rose to $18.9 million in Q1 2026 from $9.8 million in Q1 2025, largely due to legal costs associated with the company's separation and allocations for non-cash stock compensation, which may impact operational efficiency.
- Cash Reserves Status: Upon launch on April 20, 2026, First Tracks had $180 million in cash and cash equivalents, which, while substantial, may not sustain long-term testing needs if R&D progress does not accelerate, potentially affecting future market competitiveness.
See More
AnaptysBio Completes Spin-Off, Focuses on Royalty Management
- Spin-Off Completion: AnaptysBio has successfully completed its spin-off of First Tracks Biotherapeutics, distributing one share of First Tracks stock for each share of Anaptys held, marking a strategic shift aimed at enhancing shareholder value.
- Virtual Business Model: The new structure operates under a virtual business model with minimal operating expenses and limited full-time employees, projecting an EBIT margin exceeding 95%, which will enhance efficiency in managing royalties and improve profitability.
- Focus on Royalty Management: AnaptysBio will concentrate on managing financial collaborations with GSK and Vanda, particularly for Jemperli and imsidolimab, with the goal of protecting and enhancing the value of these assets to boost shareholder returns.
- Future Outlook: The company will continue trading on Nasdaq under the ticker ANAB, while First Tracks stock will also commence trading, indicating ongoing activity in the capital markets and suggesting future growth potential.
See More
First Tracks Biotherapeutics Launches with $180 Million Cash on Nasdaq
- Company Launch and Funding: First Tracks Biotherapeutics officially launches today with $180 million in cash, ensuring a two-year operational runway aimed at advancing antibody therapeutics for autoimmune and inflammatory diseases.
- Product Pipeline Overview: The company will initially focus on three development-stage assets, including the CD122 antagonist ANB033 for celiac disease and eosinophilic esophagitis, which is currently in a Phase 1b trial, indicating strong market potential.
- Shareholder Distribution Details: The spin-off was completed by distributing one share of First Tracks Bio common stock for each share of AnaptysBio held as of April 6, 2026, enhancing shareholder investment value.
- Market Outlook: CEO Daniel Faga emphasized the commitment to developing antibody therapies for autoimmune diseases, which are expected to deliver significant therapeutic benefits to patients and drive long-term value creation.
See More
